Literature DB >> 1547174

Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review.

C B Finn1, D M Luesley, E J Buxton, G R Blackledge, K Kelly, J A Dunn, S Wilson.   

Abstract

OBJECTIVE: To review the incidence of Stage I epithelial ovarian carcinoma in the West Midlands region and to identify prognostic factors that have a significant effect on survival.
DESIGN: A retrospective review of all Stage I ovarian cancer patients registered from 1.1.80 to 31.12.84.
SETTING: West Midlands Regional Cancer Registry. POPULATION: 457 patients with Stage I ovarian cancer--373 with epithelial ovarian carcinoma. MAIN OUTCOME MEASURES: Survival at censor date of 30.6.89.
RESULTS: 28% developed recurrent disease, and the overall 5-year survival of the group was 70%. Univariate analysis of all possible prognostic factors showed that stage, adjuvant chemotherapy, histological grade and type, surgical rupture of the tumour, intact capsule histologically, clinical finding of ascites and the performance of peritoneal washings were significantly associated with survival. Adequate surgical staging as defined by FIGO was not significantly associated with survival. A multivariate analysis based on the Cox proportional hazard model identified histological grade, adjuvant chemotherapy, patient age and peritoneal washings as having independent prognostic effects. Surprisingly adjuvant chemotherapy and peritoneal washings had negative effects on survival.
CONCLUSIONS: Although a retrospective review has limitations, it would appear that adequate surgical staging and adjuvant chemotherapy confer no benefit in terms of survival in Stage I disease.

Entities:  

Mesh:

Year:  1992        PMID: 1547174     DOI: 10.1111/j.1471-0528.1992.tb14393.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

1.  Routine data: a resource for clinical audit?

Authors:  M McKee
Journal:  Qual Health Care       Date:  1993-06

Review 2.  Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Authors:  D D Gibbs; M E Gore
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma.

Authors:  C Q Liu; H Sasaki; M T Fahey; A Sakamoto; S Sato; T Tanaka
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

4.  The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

Authors:  Jk Chan; K Fuh; Jy Shin; Mk Cheung; Cb Powell; L-m Chen; Ds Kapp; K Osann
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.